Pharmacokinetics and dosimetry of an α-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia Academic Article uri icon

Overview

MeSH Major

  • Bismuth
  • Leukemia, Myeloid
  • Radioimmunotherapy
  • Radioisotopes

abstract

  • This study shows that patient imaging of 213Bi, an alpha-particle emitter, labeled to HuM195 is possible and may be used to derive pharmacokinetics and dosimetry. The absorbed dose ratio between marrow, liver and spleen volumes and the whole body for 213Bi-HuM195 is 1000-fold greater than that commonly observed with beta-emitting radionuclides used for radioimmunotherapy.

publication date

  • November 1999

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 10565792

Additional Document Info

start page

  • 1935

end page

  • 46

volume

  • 40

number

  • 11